Latest Oncology News

Niraparib Plus Dostarlimab Misses the Mark in Platinum-Resistant Ovarian Cancer

Niraparib Plus Dostarlimab Misses the Mark in Platinum-Resistant Ovarian Cancer

June 25th 2022

Kristi Rosa

The combination of niraparib and dostarlimab produced a low overall response rate in patients with platinum-resistant ovarian cancer without a known BRCA mutation who had progressed and received prior bevacizumab, one that did not reach the threshold for second-stage accrual to the phase 2 MOONSTONE/GOG-3032 trial.

FDA Approves Liso-cel for Second-Line Relapsed/Refractory LBCL

FDA Approves Liso-cel for Second-Line Relapsed/Refractory LBCL

June 24th 2022

Caroline Seymour

The FDA has approved lisocabtagene maraleucel as second-line therapy for adult patients with large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

Amivantamab/Lazertinib Combo Demonstrates Durable Activity in EGFR-Mutated NSCLC

Amivantamab/Lazertinib Combo Demonstrates Durable Activity in EGFR-Mutated NSCLC

June 24th 2022

Kristi Rosa

The combination of amivantamab-vmjw and lazertinib produced encouraging responses with acceptable safety in patients with EGFR-mutated non–small cell lung cancer who expressed on osimertinib and platinum-based chemotherapy.

Wenham Discusses the Growing Treatment Landscape Across Gynecologic Cancers

Wenham Discusses the Growing Treatment Landscape Across Gynecologic Cancers

June 24th 2022

Ryan Scott

Robert Wenham, MD, MS, FACOG, FACS, discusses the current treatment landscape for patients with cervical and endometrial cancers, ADCs and PARP inhibitors in ovarian cancer, advancements in HER2-positive breast cancer, and surgical options for patients with ovarian cancer.

Tamibarotene Highlights Novel Treatment Strategy in RARA+ AML

Tamibarotene Highlights Novel Treatment Strategy in RARA+ AML

June 24th 2022

Kyle Doherty

Retinoic acid receptor α, a gene overexpressed in approximately 30% of unfit patients with newly diagnosed acute myeloid leukemia, has emerged as a potential therapeutic target.

Latest Oncology Videos

All Oncology News

PDS0101 Shows Synergistic Activity With Pembrolizumab in HPV16+ Head and Neck Squamous Cell Carcinoma

June 7th 2022

Wayne Kuznar

The combination of PDS0101 and pembrolizumab led to encouraging responses and favorable safety with no grade 3 or greater treatment-related adverse effects in patients with checkpoint inhibitor–naïve HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma, according to findings from a prespecified interim analysis of the phase 2 VERSATILE-002 study.

Rivoceranib Elicits Promising Responses in Adenoid Cystic Carcinoma

June 7th 2022

Silas Inman

The oral VEGFR2 TKI rivoceranib demonstrated an objective response rate by investigator assessed RECIST 1.1 criteria of 15.1% and a disease control rate of 64.4% for patients with recurrent or metastatic adenoid cystic carcinoma.

Zanubrutinib Plus Obinutuzumab Elicits Improved Response Rates in Relapsed/Refractory Follicular Lymphoma

June 7th 2022

Wayne Kuznar

The addition of zanubrutinib to obinutuzumab achieved an improved overall response rate, overall survival, and progression-free survival, compared with obinutuzumab alone, in patients with relapsed/refractory follicular lymphoma.

Dr. Botta on the Evaluation of CT041 in Gastric and Pancreatic Cancer

June 7th 2022

Gregory P. Botta, MD, PhD

Gregory Botta, MD, PhD, discusses the evaluation of CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

Dr. Rao on the Rationale of the CASPAR Trial in mCRPC

June 7th 2022

Arpit Rao, MD

Arpit Rao, MD, discusses the rationale and importance of the phase 3 CASPAR trial in castration-resistant prostate cancer.

Pembrolizumab Produces Prolonged Survival in NSCLC With PD-L1 TPS ≥ 90%

June 7th 2022

Ariana Pelosci

Treatment with frontline pembrolizumab demonstrated meaningful improvements in long-term survival in patients with EGFR- or ALK- wild-type non–small cell lung cancer and a tumor proportion score of at least 90% vs those with a tumor proportion score between 50% and 89%, according to 3-year findings from a correlative analysis.

Larotrectinib Delivers Durable Improvement in HRQoL in TRK Fusion Cancers

June 7th 2022

Nichole Tucker

Treatment with larotrectinib led to early onset and clinically meaningful improvements in health-related quality of life that were sustained for more than 12 months in most adult and pediatric patients with TRK fusion lung cancer, according to results from an expanded dataset.

Panitumumab Plus Intensified Chemotherapy Fails to Improve Efficacy in mCRC

June 7th 2022

Jonah Feldman

The EGFR inhibitor panitumumab plus a stronger chemotherapy regimen did not demonstrate a significant response benefit over an active chemotherapy comparator plus panitumumab in patients with metastatic colorectal cancer with unmutated RAS and BRAF.

Darolutamide Lowers Risk of Metastatic Progression in Nonmetastatic CRPC

June 7th 2022

Benjamin Saylor

Darolutamide significantly reduced the risk of metastatic progression and improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer.

Pembrolizumab/Chemoradiation Maintains Efficacy in Previously Untreated Stage III NSCLC

June 7th 2022

Ryan McDonald

Pembrolizumab plus concurrent chemoradiation, followed by single-agent pembrolizumab, maintained survival benefits in patients with previously untreated, locally advanced stage III non–small cell lung cancer.

Ribociclib Dose Reductions Do Not Affect Survival Outcomes in HR+/HER2- Advanced Breast Cancer

June 7th 2022

Lindsay Fischer

Overall survival outcomes for patients with hormone receptor–positive, HER2-negative advanced breast cancer who had dose modifications of ribociclib in the phase 3 MONALEESA-2 trial were comparable to those seen among patients who received the standard dose.

Sugemalimab and Chemotherapy Displays Significant OS Improvement in NSCLC

June 7th 2022

Conor Killmurray

Sugemalimab plus chemotherapy improved overall survival (OS) vs placebo plus chemotherapy in patients with newly diagnosed metastatic non–small cell lung cancer, irrespective of PD-L1 expression or tumor histology.

Radiotherapy Unnecessary for Some Luminal A Breast Cancers

June 7th 2022

Silas Inman

Radiotherapy can safely be omitted from treatment plans following breast conserving surgery without jeopardizing recurrence rates for patients aged 55 years and older who have low-grade, T1N0, luminal A breast cancer with a Ki67 expression of 13.25% or less, according to findings from the LUMINA study.

Select Biomarkers Signal Worse Survival Outcomes With Apalutamide/ADT in mCSPC

June 7th 2022

Jason Broderick

Circulating tumor DNA, select androgen receptor, and non-AR biomarkers have been identified as potential prognostic indicators of overall survival benefit for apalutamide plus androgen-deprivation therapy for patients with metastatic castration-sensitive prostate cancer.

Dostarlimab Elicits Clinical Complete Response Among All Treated Patients with dMMR Rectal Cancer

June 7th 2022

Brittany Lovely

Single-agent dostarlimab-gxly elicited a clinical complete response rate of 100% with no evidence of residual tumor among 14 patients with stage II/III mismatch repair–deficient locally advanced rectal cancer.

See All News